Navigation Links
Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
Date:11/25/2008

CAMBRIDGE, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will participate in the PiperJaffray Annual Health Care Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at The New York Palace Hotel in New York, NY.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

    Idenix Pharmaceuticals Contact:
    Amy Sullivan 617-995-9838 (investors)
    Teri Dahlman 617-995-9905 (media)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Idenix to Host Conference Call Discussing First Quarter 2008 Financial Results
3. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
4. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
8. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
11. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: